CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for Mary Bauer
1.85
0.00 (0.27%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.83 - 1.89
52 week 1.65 - 2.94
Open 1.88
Vol / Avg. 1.29M/2.01M
Mkt cap 333.66M
P/E     -
Div/yield     -
EPS -0.59
Shares 180.24M
Beta 1.12
Inst. own 33%
Sep 23, 2015
CTi Biopharma Corp Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Aug 6, 2015
Q2 2015 CTi Biopharma Corp Earnings Call - 4:30PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 CTi Biopharma Corp Earnings Release - 4:00PM EDT - Add to calendar
Jun 24, 2015
CTi Biopharma Corp at ROTH Healthcare Day - London
May 6, 2015
Q1 2015 CTi Biopharma Corp Earnings Call - Webcast
May 6, 2015
Q1 2015 CTi Biopharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1058.83% -156.85%
Operating margin -1007.44% -143.54%
EBITD margin - -105.32%
Return on average assets -149.15% -101.32%
Return on average equity -385.96% -220.85%
Employees 125 -
CDP Score - -

Address

3101 Western Ave Ste 600
SEATTLE, WA 98121-3047
United States - Map
+1-206-2827100 (Phone)
+1-206-2846206 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

Officers and directors

Phillip M. Nudelman Ph.D. Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
James A. Bianco M.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Louis A. Bianco Executive Vice President, Finance and Administration, and Chief Governance Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack W. Singer M.D. Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.
Age: 72
Bio & Compensation  - Reuters
Matthew J. Plunkett Ph.D. Executive Vice President, Corporate Development
Age: 43
Bio & Compensation  - Reuters
Bruce J. Seeley Executive Vice President and Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 48
Bio & Compensation  - Reuters
Karen Ignagni Director
Age: 61
Bio & Compensation  - Reuters
John H. Bauer Independent Director
Age: 74
Bio & Compensation  - Reuters